(Reuters) -Akero Therapeutics said its lead drug to treat patients with a severe type of fatty liver disease missed the main goal in a mid-stage trial, sending its shares tumbling 60% in early trading ...

(Reuters) - Akero Therapeutics Inc said on Monday data from a mid-stage study showed its experimental therapy reduced liver fat by 65% in certain patients with a type of fatty liver disease called ...

Longer treatment with an Akero Therapeutics drug in development for the liver disease MASH led to better results, including improvement in fibrosis, the liver scarring that is a hallmark of the ...

39% of patients in the 50mg EFX group demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, a significant finding with a p-value of 0.009 compared to placebo. Data suggests that EFX ...

Things were going pretty well in the NASH landscape with Madrigal Therapeutics finally submitting a request to approve a treatment, but yesterday the space came crashing back down to reality with the ...

According to preliminary results released Tuesday, the Akero drug efruxifermin led to at least one stage of improvement in a measure of fibrosis, or liver scarring, that develops from the fatty liver ...

STOCKHOLM (Reuters) -Novo Nordisk (NVO) said on Thursday it would buy U.S.-based Akero Therapeutics (AKRO) for up to $5.2 billion to add its promising experimental liver disease drug, in the first ...

Akero Therapeutics recently presented results from its Phase 2b SYMMETRY trial at the EASL Congress 2025, showcasing the efficacy of efruxifermin (EFX) in improving fibrosis in patients with ...

Akero's experimental NASH drug efruxifermin (EFX) missed its primary endpoint in a phase 2b study. However, statistically significant improvement was seen in NASH resolution with patients receiving ...

Advances Akero’s Mission of Bringing Novel Therapies to Patients with High Unmet Medical Needs SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (AKRO), a ...